US FDA accepts new Drug Application for vericiguat for review

The application for this orally administered soluble guanylate cyclase stimulator seeks approval for its use to reduce the risk of CV death and heart failure (HF) hospitalization following a worsening HF event in patients with symptomatic chronic HF with reduced ejection fraction


Biospace Inc.